drugset / Trial / NCT01113320

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

NCT01113320

Phase 2 Completed 26 enrolled Newron Pharmaceuticals SPA
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria and Canada. The research trial will last until December 2011.

Timeline

Start
2010-04
Primary completion
2011-11
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Safinamide Small molecule 300 mg

Indications